MiNK Therapeutics, Inc. INKT 深 滬
等待開盤 09-10 09:30:00 美东时间
15.36
-0.470
-2.97%
華盛通- 最 高16.01
- 今 開15.50
- 成交量 3.86万股
- 最 低 14.95
- 昨 收 15.83
- 總市值 6122.04万
- 52周最高 76.00
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 4.632
- 委 比 0.00%
- 總股本 398.57万
- 歷史最高 221.55
- 量 比 0.68
- 振 幅 6.70%
- 歷史最低 4.632
- 每 手 1
- 風險率 0.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MiNK Therapeutics shares are trading lower after the company reported a Q2 EPS miss.
MiNK Therapeutics shares are trading lower after the company reported a Q2 EPS ...
08-14 20:54
MiNK Therapeutics Q2 EPS $(1.06) Misses $(0.46) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.46) by 132.97 percent. This is a 45.21 percent decrease over losses of $(0.73) per share
08-14 19:33
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
MiNK Therapeutics announced Q2 2025 financial results, highlighting a strengthened balance sheet with $1.6 million in cash and $13 million raised post-quarter, extending runway to mid-2026. Key achievements include durable complete remission in metastatic testicular cancer, new grants for GvHD clinical trials, and progress in a Phase 2 gastric cancer study. Net loss was $4.2 million, up from $2.7 million in Q2 2024, reflecting ongoing program act...
08-14 11:30
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
<p>MiNK Therapeutics announced it will release its Q2 2025 financial results before the market opens on August 14, 2025. A conference call and webcast will be held at 8:30 a.m. ET that day to discuss the results. The dial-in numbers are 646-307-1963 (New York) and 800-715-9871 (USA & Canada), with conference ID 1149380. A live webcast and replay will be available on the Company’s website.</p>
07-31 12:30
暴涨730%！iNKT疗法用一个临床案例点燃实体瘤革命，中国追赶在即
（来源：求实药社） 2.6亿市值跃升：一个临床案例如何撼动华尔街？ 2025年7月11日，MiNK Therapeutics（NASDAQ: INKT）宣布其异...
07-16 12:01
MiNK Therapeutics Enters $50M Sales Agreement with B. Riley
MiNK Therapeutics ( ($INKT) ) has shared an announcement. On July 15, 2025, MiN...
07-15 19:28
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
MiNK Therapeutics highlights the unique potential of iNKT cells in treating solid tumors through their allogeneic iNKT platform, agenT-797, and CAR-iNKT therapies. Published in *Frontiers in Immunology*, their research demonstrates iNKT cells' ability to remodel the tumor microenvironment, overcome immune resistance, and deliver scalable, off-the-shelf cell therapies without lymphodepletion or genetic modification. Clinical data show durable resp...
07-15 12:21
MiNK Therapeutics Announces Clinical Trial Success
MiNK Therapeutics ( ($INKT) ) has provided an announcement. On July 11, 2005, M...
07-14 20:15
周末要闻：特朗普称对墨西哥、欧盟征收30%关税 白宫欲借“装修门”解雇鲍威尔 欧盟推迟对美关税反制措施
欲览更多环球财经资讯，请移步7×24小时实时财经新闻 道指期货周一开盘下跌200点 特朗普对墨西哥和欧盟征收30%关税 上周市场回顾 收盘：美股周五收跌 特...
07-14 06:44
